title: Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
abstract: B7-H3 (CD276) is an important immune checkpoint member of the B7 and CD28 families. Induced on antigen-presenting cells, B7-H3 plays an important role in the inhibition of T-cell function. Importantly, B7-H3 is highly overexpressed on a wide range of human solid cancers and often correlates with both negative prognosis and poor clinical outcome in patients. Challenges remain to identify the receptor(s) of B7-H3 and thus better elucidate the role of the B7-H3 pathway in immune responses and tumor evasion. With a preferential expression on tumor cells, B7-H3 is an attractive target for cancer immunotherapy. Based on the clinical success of inhibitory immune checkpoint blockade (CTLA-4, PD-1, and PD-L1), mAbs against B7-H3 appear to be a promising therapeutic strategy worthy of development. An unconventional mAb against B7-H3 with antibody-dependent cell-mediated cytotoxicity is currently being evaluated in a phase I clinical trial and has shown encouraging preliminary results. Additional therapeutic approaches in targeting B7-H3, such as blocking mAbs, bispecific mAbs, chimeric antigen receptor T cells, small-molecule inhibitors, and combination therapies, should be evaluated, as these technologies have already shown positive results in various cancer settings. A better understanding of the B7-H3 pathway in humans will surely help to further optimize associated cancer immunotherapies. Clin Cancer Res; 22(14); 3425-31. ©2016 AACR.
authors.affiliation: Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York.
authors.forename: Elodie
authors.initials: E
authors.lastname: Picarda
authors.affiliation: Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York.
authors.forename: Kim C
authors.initials: KC
authors.lastname: Ohaegbulam
authors.affiliation: Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York.|Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.|Department of Urology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.
authors.forename: Xingxing
authors.initials: X
authors.lastname: Zang
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects / Q000276:immunology; D000938:Antigen-Presenting Cells / Q000187:drug effects / Q000276:immunology; D060887:B7 Antigens / Q000276:immunology*; D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D015398:Signal Transduction / Q000187:drug effects / Q000276:immunology*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D060887:B7 Antigens; C423237:CD276 protein, human